SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-25-002591
Filing Date
2025-01-10
Accepted
2025-01-10 17:00:23
Documents
13
Period of Report
2025-01-07
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm252980d1_8k.htm   iXBRL 8-K 29654
  Complete submission text file 0001104659-25-002591.txt   197977

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA enzn-20250107.xsd EX-101.SCH 3006
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE enzn-20250107_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE enzn-20250107_pre.xml EX-101.PRE 22353
15 EXTRACTED XBRL INSTANCE DOCUMENT tm252980d1_8k_htm.xml XML 3247
Mailing Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016
Business Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016 732-980-4500
ENZON PHARMACEUTICALS, INC. (Filer) CIK: 0000727510 (see all company filings)

IRS No.: 222372868 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-12957 | Film No.: 25523775
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)